- |||||||||| sodium phenylbutyrate / Generic mfg.
Journal: Investigation of the lipidomic changes in differentiated glioblastoma cells after drug treatment using MALDI-MS. (Pubmed Central) - Jul 11, 2021 In our study, glioblastoma cell line U87-MG cells were treated by inducers of sodium phenylbutyrate (SPB) and all-trans retinoic acid (ATRA)...Most of the glycerophosphocholines (PC) with an increasing abundance are unsaturated PCs (PC (38:1), 816 m/z; PC (36:1), 788 m/z; PC (31:1), 725 m/z), and those decreasing are saturated PCs (PC (32:0), 734 m/z). These results provide the lipidomic differentiation which may be a significant guidance for evaluating the therapeutic effect of tumor therapy.
- |||||||||| sodium phenylbutyrate / Generic mfg.
Preclinical, Journal: Exploring mechanistic links between extracellular BCAA & muscle insulin resistance: an in vitro approach. (Pubmed Central) - Jan 8, 2021 Using skeletal muscle cells, we aimed to determine whether continued exposure of high extracellular BCAA would result in impaired insulin signaling and whether the compound sodium phenylbutyrate (PB), which induces BCAA metabolism, would lower extracellular BCAA, thereby alleviating their potentially inhibitory effects on insulin-mediated signaling...PB significantly reduced media BCAA and branched-chain keto acid (BCKA) concentrations, and increased phosphorylation of AKT (+20±2%; P<0.05 vs. Ctl) and AS160 (+24±2%; P<0.05 vs. Ctl), however insulin-stimulated glycogen synthesis was further reduced upon PB treatment. Continued exposure of high BCAA resulted in impaired intracellular insulin signalling and glycogen synthesis, and while forcing BCAA catabolism using PB resulted in increases in proteins important for regulating glucose uptake, PB did not prevent the impairments in glycogen synthesis with BCAA exposure.
- |||||||||| sodium phenylbutyrate / Generic mfg.
Journal: Sodium Phenylbutyrate-Taurursodiol for ALS. Reply. (Pubmed Central) - Dec 20, 2020 Continued exposure of high BCAA resulted in impaired intracellular insulin signalling and glycogen synthesis, and while forcing BCAA catabolism using PB resulted in increases in proteins important for regulating glucose uptake, PB did not prevent the impairments in glycogen synthesis with BCAA exposure. No abstract available
- |||||||||| Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Enrollment change, Trial completion date, Trial primary completion date: Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Na (clinicaltrials.gov) - Feb 17, 2020 P4, N=18, Recruiting, Trial completion date: Oct 2019 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Dec 2020 N=30 --> 18 | Trial completion date: Mar 2020 --> Mar 2023 | Trial primary completion date: Dec 2019 --> Sep 2022
- |||||||||| sodium phenylbutyrate / Generic mfg.
Trial completion, Trial primary completion date: Phenylbutyrate Therapy for Maple Syrup Urine Disease (clinicaltrials.gov) - Mar 6, 2019 P2/3, N=20, Completed, N=14 --> 0 | Active, not recruiting --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Sep 2017
- |||||||||| Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Enrollment open, Trial initiation date, Trial primary completion date: Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Na (clinicaltrials.gov) - Dec 22, 2017 P4, N=30, Recruiting, Initiation date: Apr 2018 --> Feb 2018 Not yet recruiting --> Recruiting | Initiation date: Nov 2017 --> Jan 2018 | Trial primary completion date: Sep 2018 --> Dec 2019
- |||||||||| Vesanoid (tretinoin) / Roche
Trial completion, Combination therapy: Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 28, 2017 P1, N=0, Completed, Not yet recruiting --> Recruiting | Initiation date: Nov 2017 --> Jan 2018 | Trial primary completion date: Sep 2018 --> Dec 2019 No longer recruiting --> Completed
- |||||||||| sodium phenylbutyrate / Generic mfg.
Trial primary completion date: Phenylbutyrate Therapy for Maple Syrup Urine Disease (clinicaltrials.gov) - Feb 1, 2017 P2/3, N=20, Active, not recruiting, No longer recruiting --> Completed Trial primary completion date: Jun 2015 --> Feb 2017
- |||||||||| sodium phenylbutyrate / Generic mfg.
Enrollment change, Trial primary completion date: Phenylbutyrate Therapy for Maple Syrup Urine Disease (clinicaltrials.gov) - Jan 31, 2017 P2/3, N=20, Active, not recruiting, Trial primary completion date: Jun 2015 --> Feb 2017 N=40 --> 20 | Trial primary completion date: Sep 2016 --> Jun 2015
- |||||||||| sodium phenylbutyrate / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Immune Reconstitution in HIV Disease (IREHIV) (clinicaltrials.gov) - Feb 5, 2016 P2, N=279, Completed, Recruiting --> Completed | Phase classification: P4 --> PN/A | Trial primary completion date: Mar 2018 --> Oct 2015 Active, not recruiting --> Completed | N=198 --> 279 | Trial primary completion date: Dec 2015 --> Aug 2015
- |||||||||| sodium phenylbutyrate / Generic mfg.
Trial completion, Trial primary completion date: IRETB: Immune Reconstitution in Tuberculosis Disease (clinicaltrials.gov) - Feb 5, 2016 P2, N=390, Completed, Active, not recruiting --> Completed | N=198 --> 279 | Trial primary completion date: Dec 2015 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015
- |||||||||| sodium phenylbutyrate / Generic mfg.
Enrollment closed, Trial primary completion date: Phenylbutyrate Therapy for Maple Syrup Urine Disease (clinicaltrials.gov) - Jan 27, 2016 P2/3, N=40, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016
- |||||||||| sodium phenylbutyrate / Generic mfg.
Enrollment closed: Immune Reconstitution in HIV Disease (IREHIV) (clinicaltrials.gov) - Jul 9, 2015 P2, N=198, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Active, not recruiting
- |||||||||| sodium phenylbutyrate / Generic mfg.
Enrollment closed: IRETB: Immune Reconstitution in Tuberculosis Disease (clinicaltrials.gov) - Jul 9, 2015 P2, N=355, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
|